Nannan Zhang
Senior Director, Translational & Biomarker Research Abbisko Therapeutics
Nannan Zhang is a seasoned biologist and drug hunter with more than 16 years of drug discovery and development experience in pharmaceutical industry. She has led or participated numerous innovative programs, spanning from early discovery to translational research and clinical development. Before joining Abbisko Therapeutics, she held positions at R&D centers of GSK and Eli Lilly in China. Dr. Zhang commenced her undergraduate studies at Shanghai Jiao Tong University and obtained a B.S. degree in Biology. She later pursued her Ph.D. degree in Biochemistry and Molecular Biology from Shanghai Institutes for Biological Science, Chinese Academy of Sciences.
Seminars
Wednesday 12th November 2025
Harnessing Next Generation Sequencing to Advance FGFR Inhibitor Development
4:10 pm
- Overview of the development history of FGFR inhibitors
- Exploring the role of next generation sequencing in accelerating FGFR inhibitor discovery and development
- Showcasing a case study from the early-stage development of an FGFR inhibitor
